Antipsychotic Drugs Market 2025 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

Page: 215 | Report Code: LS250131 | Research Suite: Report (PDF) & Market Data (Excel)

NOTE: Due to exhaustive nature of content, full ToC can't be uploaded. Please request Sample Pages to receive full table of content. 

The global antipsychotic drugs market is valued to be USD 24.4 billion in 2023, and a CAGR of 6.1% is expected to drive growth in the market. Increasing growth in the cases of mental disorders and growing awareness about the mental health issues are driving demand in the market. An increasing number of patients suffering from schizophrenia and bipolar disorders are driving growth in the market significantly.

Rising healthcare expenditure and lifestyle imbalance of people due to stiff competition in every endeavor. According to data published in an article of WHO, every single person out of 8 is suffering from the mental disease.

Mental health campaigns reduce stigma and encourage people to seek treatment. Advancements in early diagnosis techniques help in identifying psychotic disorders earlier. Earlier patients with Alzheimer’s and Parkinson’s disease often develop psychosis, increasing demand for atypical antipsychotics.


Growth Drivers

Growing investments in mental health facilities support market growth. Government initiatives and expanding mental health coverage in insurance policies are making treatments more accessible. Pharmaceutical companies are investing in advanced formulations like digital pills and personalized medicine. Regulatory agencies like the FDA and EMA are fast-tracking approvals for innovative treatments.

New drugs with fewer side effects are gaining market share. Long-acting injectables improve patient compliance and reduce relapse rates. Growing investment in mental health facilities supports market growth significantly. Government initiatives in promoting awareness about mental health are driving growth in the market. An increasing number of patients with Parkinson's and schizophrenia-like diseases are driving growth in the market.

The increasing geriatric population in all over world is more susceptible to dementia-related psychotics. Reduction in stigma leading to higher treatment adoption is driving growth significantly in the market. Growth in psychiatric health infrastructure, and affordable treatment due to insurance and reimbursement policies are driving growth in the market. Increasing demand for telemedicine to access psychiatric care significantly is driving growth in the market. Rising prevalence of the cases of insomnia, depression, and anxiety is driving significant growth in the market.

Segmentation

Drug Outlook

·         Risperidone

·         Quetiapine

·         Olanzapine

·         Aripiprazole

·         Brexpiprazole

·         Paliperidone Palmitate

·         Others

Therapeutic Class

·         First Generation

·         Second Generation

·         Third Generation

Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Middle East and Africa

·         Europe

Antipsychotic Drugs Market by Distribution Channel Segmentation

On the basis of the distribution channel, the antipsychotic drugs market is segmented into hospital pharmacies, online pharmacies, and online pharmacies. Hospitals treat severe mental illness such as schizophrenia, bipolar disorder, and acute psychosis, where immediate and controlled medical administration is crucial.


Hospital pharmacies stock both typical and atypical antipsychotics, including new formulations like long-acting injectables that require medical supervision. Some high-cost and specialized drugs are mainly available in hospital settings. Growing investment in mental health facilities supports market growth significantly. Government initiatives in promoting awareness about mental health are driving growth in the market.

Bulk purchasing by hospitals makes them a dominant distribution channel. Many psychiatric emergencies require immediate access to antipsychotic medications. Reimbursement policies and insurance coverage favor hospital-administered medications. Due to higher patient footfall, the hospital pharmacies are witnessing significant growth in the market.

Online pharmacies, due to rising growth in e-commerce, are also witnessing significant growth in the market. Home delivery eliminates the need for physically visiting pharmacies, which is beneficial for patients with severe psychiatric conditions or mobility issues. Online pharmacies seamlessly integrate with e-prescription systems, making it easier for patients to get prescribed antipsychotics without visiting a hospital.

Online pharmacies offer discounted prices, promotions, and bulk purchase options, making them a cost-effective alternative to traditional pharmacies. Many countries have relaxed regulations to allow the sale of prescription drugs through licensed online pharmacies.

Regional Outlook

On the basis of the regions, the antipsychotic drugs market is segmented into 5 regions: Asia Pacific, North America, Latin America, the Middle East and Africa, and Europe. North America is the leading segment in the market due to the high incidence of schizophrenia, bipolar disorders, and depression. The U.S. has one of the highest diagnosis rates for psychiatric conditions. Strong healthcare infrastructure and reimbursement policies are driving growth in the market. Key players such as Johnson and Johnson, Pfizer, Eli Lilly, and Bristol Myers Squibb are headquartered in North America. Faster adoption of new drug approvals by the FDA compares to other regions. U.S. government funding for mental health initiatives, such as the National Institute of Mental Health, is driving growth in the market.

Telepsychiatry and digital mental health platforms are expanding access to treatment. Asia Pacific is growing rapidly due to increasing mental health awareness, urbanization, and changing lifestyles. Increasing urbanization and changing lifestyles are driving growth in the market. China, Japan, India, and South Korea are witnessing significant growth due to rapidly growing populations and rising demand for affordable generics and innovative treatments. Stigma, limited access to psychiatric care, and lower insurance coverage slow market dominance in comparison to North America. An increasing geriatric population and well-established healthcare infrastructure are driving growth in the European region. Countries like Germany, France, Russia, Turkey, Sweden, Norway, Denmark, and Italy are the countries witnessing significant growth in the market. The presence of key players in the region is acting like a catalyst in the region.

Despite challenges in mental health care access and quality, countries like Brazil are implementing policies and clinical initiatives to raise awareness and improve treatment availability. In 2022, Argentina partnered with the WHO for the Director General’s special initiatives for mental health aiming to enhance mental health services and reach approximately 5.2 million Argentinians. The Middle East and Africa region is witnessing growth in the market due to rising healthcare spending and awareness initiatives. South Africa had the highest percentage of individuals with mental health disorders among 64 countries surveyed. Due to heightened mental health awareness, government support and initiatives these regions are witnessing significant market growth.


Key Players

·         H. Lundbeck A/S

·         Otsuka Pharmaceutical Co., Ltd.

·         Janssen Global Services, LLC

·         Eli Lilly and Company

·         AbbVie, Inc.

·         Teva Pharmaceutical Industries Ltd.

·         Dr. Reddy’s Laboratories Ltd.

·         Sumitomo Pharma

·         Alkermes

·         Bristol-Myers Squibb Company

·         Other Players

Buy Report